Table of Contents Author Guidelines Submit a Manuscript
Infectious Diseases in Obstetrics and Gynecology
Volume 2009, Article ID 456717, 8 pages
http://dx.doi.org/10.1155/2009/456717
Research Article

Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings

1Pediatric, Adolescent and Maternal AIDS Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD 20892, USA
2Clinical Trials and Surveys Corp., Owings Mills, MD 21117, USA
3Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
4Quest Diagnostics, Baltimore, MD 21227, USA
5Department of Pediatrics, State University of New York Downstate, Brooklyn, NY 11203, USA
6Department of Pediatrics, University of Illinois, Chicago, IL 60612, USA
7Department of Pediatrics, Baylor University, Houston, TX 77030, USA
8Department of Pediatrics, Columbia University, New York, NY 10032, USA
9Department of Pediatrics, University of Puerto Rico, San Juan, PR 00936, USA

Received 15 June 2009; Accepted 25 August 2009

Academic Editor: Susan Cu-Uvin

Copyright © 2009 D. H. Watts et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Centers for Disease Control and Prevention, “Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States,” Morbidity and Mortality Weekly Report, vol. 47, no. RR-2, pp. 1–30, 1998. View at Google Scholar · View at Scopus
  2. R. E. Tuomala, H. Watts, D. Li et al., “Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 4, pp. 449–473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. E. R. Cooper, M. Charurat, L. Mofenson et al., “Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, no. 5, pp. 484–494, 2002. View at Google Scholar · View at Scopus
  4. A. J. Krolewiecki, C. Zala, C. Vanzulli et al., “Safe treatment interruptions in patients with nadir CD4 counts of more than 350 cells/µL: a randomized trial,” Journal of Acquired Immune Deficiency Syndromes, vol. 41, no. 4, pp. 425–429, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Ananworanich, A. Gayet-Ageron, M. Le Braz et al., “CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial,” The Lancet, vol. 368, no. 9534, pp. 459–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Marchou, P. Tangre, I. Charreau et al., “Intermittent antiretroviral therapy in patients with controlled HIV infection,” AIDS, vol. 21, no. 4, pp. 457–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Danel, R. Moh, A. Minga et al., “CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial,” The Lancet, vol. 367, no. 9527, pp. 1981–1989, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. W. M. El-Sadr, J. D. Lundgren, J. D. Neaton et al., “CD4+ count-guided interruption of antiretroviral treatment,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2283–2296, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. Centers for Disease Control and Prevention, “Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents,” Morbidity and Mortality Weekly Report, vol. 47, no. RR-5, pp. 1–82, 1998. View at Google Scholar
  10. A. D. Bardeguez, D. E. Shapiro, L. M. Mofenson et al., “Effect of cessation of zidovudine prophylaxis to reduce vertical transmission on maternal HIV disease progression and survival,” Journal of Acquired Immune Deficiency Syndromes, vol. 32, no. 2, pp. 170–181, 2003. View at Google Scholar · View at Scopus
  11. D. H. Watts, J. Lambert, E. R. Stiehm et al., “Progression of HIV disease among women following delivery,” Journal of Acquired Immune Deficiency Syndromes, vol. 33, no. 5, pp. 585–593, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. E. R. Stiehm, J. S. Lambert, L. M. Mofenson et al., “Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of pediatric AIDS clinical trials group protocol 185,” Journal of Infectious Diseases, vol. 179, no. 3, pp. 567–575, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Martin, L. Navaratne, W. Khan et al., “Pregnant women with HIV infection can expect healthy survival: three-year follow-up,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, no. 2, pp. 186–192, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Tungsiripat, H. Drechsler, and J. A. Aberg, “Discontinuation of antiretroviral therapy postpartum: no evidence for altered viral set point,” Journal of Acquired Immune Deficiency Syndromes, vol. 44, no. 1, pp. 116–117, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. F. Onen, D. Nurutdinova, S. Sungkanuparph, D. Gase, K. Mondy, and E. T. Overton, “Effect of postpartum HIV treatment discontinuation on long-term maternal outcome,” Journal of the International Association of Physicians in AIDS Care, vol. 7, no. 5, pp. 245–251, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. A. R. Sheon, H. E. Fox, K. C. Rich et al., “The women and infants transmission study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data,” Journal of Women's Health, vol. 5, no. 1, pp. 69–78, 1996. View at Google Scholar · View at Scopus
  17. Centers for Disease Control and Prevention, “1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults,” Journal of the American Medical Association, vol. 269, no. 6, pp. 729–730, 1993. View at Google Scholar
  18. P. J. Diggle, K. Y. Liang, and S. L. Zeger, Analysis of Longitudinal Data, Oxford University Press, New York, NY, USA, 1994.
  19. N. M. Laird and J. H. Ware, “Random-effects models for longitudinal data,” Biometrics, vol. 38, no. 4, pp. 963–974, 1982. View at Google Scholar · View at Scopus
  20. D. Cox, “Regression models and life tables,” Journal of the Royal Statistical Society: Series B, vol. 34, pp. 187–220, 1972. View at Google Scholar
  21. K. C. Rich, J. N. Siegel, C. Jennings, R. J. Rydman, and A. L. Landay, “CD8+ lymphocytes in pregnancy and HIV infection: characterization of CD8+ subpopulations and CD8+ noncytotoxic antiviral activity,” AIDS Research and Human Retroviruses, vol. 15, no. 7, pp. 665–670, 1999. View at Publisher · View at Google Scholar · View at Scopus
  22. P. M. Garcia, L. A. Kalish, J. Pitt et al., “Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission,” The New England Journal of Medicine, vol. 341, no. 6, pp. 394–402, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Emery, J. A. Neuhaus, A. N. Phillips et al., “Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study,” Journal of Infectious Diseases, vol. 197, no. 8, pp. 1133–1144, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Mikyas, N. Aziz, N. Harawa et al., “Immunologic activation during pregnancy: serial measurement of lymphocyte phenotype and serum activation molecules in HIV-infected and uninfected women,” Journal of Reproductive Immunology, vol. 33, no. 2, pp. 157–170, 1997. View at Publisher · View at Google Scholar · View at Scopus
  25. M. D. Hazenberg, S. A. Otto, B. H. B. van Benthem et al., “Persistent immune activation in HIV-1 infection is associated with progression to AIDS,” AIDS, vol. 17, no. 13, pp. 1881–1888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  26. P. W. Hunt, J. N. Martin, E. Sinclair et al., “T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency vires-infected patients with sustained viral suppression during antiretroviral therapy,” Journal of Infectious Diseases, vol. 187, no. 10, pp. 1534–1543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. P. K. Drain, R. Kupka, G. I. Msamanga, W. Urassa, F. Mugusi, and W. W. Fawzi, “C-reactive protein independently predicts HIV-related outcomes among women and children in a resource-poor setting,” AIDS, vol. 21, no. 15, pp. 2067–2075, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. S. A. Riddler, X. Li, H. Chu et al., “Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy,” HIV Medicine, vol. 8, no. 5, pp. 280–287, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. S. G. Lakoski, M. Cushman, M. Criqui et al., “Gender and C-reactive protein: data from the multiethnic study of atherosclerosis (MESA) cohort,” American Heart Journal, vol. 152, no. 3, pp. 593–598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Sudhir, “Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 5, pp. 3100–3105, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Khuseyinova and W. Koenig, “Biomarkers of outcome from cardiovascular disease,” Current Opinion in Critical Care, vol. 12, no. 5, pp. 412–419, 2006. View at Publisher · View at Google Scholar · View at Scopus